Skip to content
value.today

AstraZeneca PLC vs Gilead Sciences, Inc.

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • AstraZeneca PLC is the larger company by market value: $242.6 B against $193.5 B for Gilead Sciences, Inc., 1.3 times as much (market caps of Aug 1, 2026 for AstraZeneca PLC and Oct 26, 2026 for Gilead Sciences, Inc.). AstraZeneca PLC's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
  • AstraZeneca PLC had more revenue: $58.7 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025.
  • AstraZeneca PLC earned more: net income of $10.2 B against $8.5 B for Gilead Sciences, Inc.
  • Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 17.4% for AstraZeneca PLC.
  • AstraZeneca PLC employs more people: 89,900 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $653,382 of revenue at AstraZeneca PLC and $1,731,941 at Gilead Sciences, Inc.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

0581171752342020202120222023202420252026AstraZeneca PLC 179Gilead Sciences, Inc. 234

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$15B$29B$44B$59B201720182019202020212022202320242025AstraZeneca PLC $59BGilead Sciences, Inc. $29B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureAstraZeneca PLC
AZN · #76 in the world
Gilead Sciences, Inc.
GILD · #104 in the world
Profile
Country🇬🇧 UK🇺🇸 USA
SectorHealthcareHealthcare
IndustryPharmaceuticalPharmaceutical
Founded19991987
Size
Market cap$242.6 B$193.5 B
Revenue$58.7 B$29.4 B
Net income$10.2 B▲ best$8.5 B
Employees89,90017,000
Valuation
P/E ratio23.7×—
Price to sales4.1×6.3×
Price to book5.0×8.5×
Free cash flow yield4.8%4.9%▲ best
Profitability
Gross margin81.9%—
Operating margin23.4%—
Net margin17.4%—
Return on equity22.9%—
Return on invested capital17.5%—
Growth
Revenue growth8.6%—
Revenue growth, 3 years a year9.8%—
Earnings per share growth45.3%—
Financial strength
Debt to equity0.5×—
Interest cover8.1×—
Cash
Free cash flow margin20.0%—
Shareholder returns
Dividend yield2.0%—
Shareholder yield2.3%—
Strength scores
Piotroski F-score8 of 9—
Altman Z-score zonesafe—
Data as ofMarket cap Aug 2026; ratios FY2025Market cap Oct 2026

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, AstraZeneca PLC or Gilead Sciences, Inc.?

AstraZeneca PLC is the larger company by market value: $242.6 B against $193.5 B for Gilead Sciences, Inc., 1.3 times as much (market caps of Aug 1, 2026 for AstraZeneca PLC and Oct 26, 2026 for Gilead Sciences, Inc.). AstraZeneca PLC's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.

Which makes more money, AstraZeneca PLC or Gilead Sciences, Inc.?

AstraZeneca PLC had more revenue: $58.7 B against $29.4 B for Gilead Sciences, Inc., both in the year to December 2025. AstraZeneca PLC earned more: net income of $10.2 B against $8.5 B for Gilead Sciences, Inc.

Which is more profitable, AstraZeneca PLC or Gilead Sciences, Inc.?

Gilead Sciences, Inc. keeps more of each dollar of sales: a net margin of 28.9% against 17.4% for AstraZeneca PLC.

Which has more employees, AstraZeneca PLC or Gilead Sciences, Inc.?

AstraZeneca PLC employs more people: 89,900 against 17,000 at Gilead Sciences, Inc. Each employee brings in about $653,382 of revenue at AstraZeneca PLC and $1,731,941 at Gilead Sciences, Inc.

Sources#

Every figure on this page comes from these, with the date shown next to it.